SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.
SIGA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for SIGA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Siga Technologies Inc ranked in the 11th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Siga Technologies Inc, consider:
The company's compound free cash flow growth rate over the past 5.26 years comes in at -0.1%; that's greater than merely 13.91% of US stocks we're applying DCF forecasting to.
As a business, SIGA is generating more cash flow than merely 16.43% of positive cash flow stocks in the Healthcare.
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 0.05% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
BHC, EW, QGEN, SRDX, and COO can be thought of as valuation peers to SIGA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
SIGA Technologies (SIGA) announces that the Public Health Agency of Canada (or PHAC) has awarded a contract to Meridian Medical Technologies, a Pfizer Company for the purchase up to ~$33M of oral TPOXX® (tecovirimat) within five years. As with all international sales of TPOXX, Meridian is the counterparty to the contract and...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference at 8:00 a.m. ET on Thursday, September 17, 2020. To access the live webcast, please visit the Company's website at www.siga.com under the Events & Presentations tab in the Investor Relations section, or by clicking here. A replay will be available for a limited time following the presentation.ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health s...